Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer

Peters S.Shaw A.T.Besse B.Felip E.Solomon B.J.Soo R.A.Bearz A.Gadgeel S.M.CHIA-CHI LINKao S.Seto T.Masters E.T.Abbattista A.Clancy J.S.Thurm H.Reisman A.Peltz G.Ross Camidge D.2022-09-152022-09-1520200169-5002https://www.scopus.com/inward/record.uri?eid=2-s2.0-85083670459&doi=10.1016%2fj.lungcan.2020.02.011&partnerID=40&md5=16d174aea8615264266e39ba30253276https://scholars.lib.ntu.edu.tw/handle/123456789/620235[SDGs]SDG3Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancerjournal article10.1016/j.lungcan.2020.02.011323442482-s2.0-85083670459